Xiaohe (Stella) Cai
Research Scientist I
Stella Cai’s work focuses on gene therapy for hemophilia.
She received an MS degree in neuro-endocrinology from a university in China and an MS in biotechnology from Johns Hopkins University.
She is a proud member of Seattle Children’s Research Institute’s Retaining Excellence Program.
Alex Chen, PhD
Alex Chen focuses on improving the current treatment for hemophilia using various new technologies including gene therapy and immunotherapy.
He received his PhD from the bioengineering department at the University of Washington.
Chun-Yu Chen’s current work uses gene therapy to try and rescue hemophilia A mouse models.
He received a PhD from the Department of Clinical Laboratory Sciences and Medical Biotechnology at National Taiwan University’s College of Medicine.
Thomas Derezes is working on a molecular cloning project in the Miao Lab and helping make microbubbles used for treatment.
He is an undergraduate at the University of Washington, where he studies molecular, cellular and developmental biology.
Research Technician I
Richard Fu’s primary research interests are in gene therapy, immunotherapy, hematology and immunology. His work in the Miao Lab centers around creating chimeric antigen receptor-engineered regulatory T cells. He also assists in the lab’s lentivirus and immune modulation project.
Fu received a bachelor’s degree from Taipei Medical University and is a graduate student in biomedical regulatory affairs at the University of Washington
Chong Li’s work focuses on gene therapy in hemophilia A by lentivirus vectors, with special emphasis on treatment studies in hemophilia A large animals. Additionally, she is interested in targeting lentivirus development studies.
Li is currently leading a large animal project on factor VIII lentivirus victors targeting expression in platelets. She is also working on factor VIII lentivirus gene therapy in a mobilization mouse model, and doing validation work on lentivectors targeting CD133 hematopoietic stem cells.
She worked at the Novartis Medical Research Institute for six years, then received a PhD from Shanghai Jiaotong University in 2016.
Wu Li, PhD
Wu Li investigates clinically feasible protocols for ultrasound-mediated gene delivery (UMGD) using imaging and fluoroscopy techniques in various animal models to aid the translation of the novel UMGD technology into human applications.
She received her MD degree at Southeast University Medical College, Nanjing, China; her MS degree in human anatomy and embryology from Xinjiang Medical University at Urumqi, China; and her PhD degree from Shanghai Medical School, Fudan University, Shanghai, China. She previously served as attending physician and radiologist, and then postdoctoral fellow at Shanghai Jiaotong University, Shanghai, China.
Research Scientist I
Meghan Lyle’s core research interest is immunology. She is currently investigating ways to induce tolerance to factor VIII in hemophilia A mice.
She holds a BS in biology from the University of Washington.
Research Scientist I
Dominic Tran’s work focuses on nonviral gene therapy and delivery to correct the hemophiliac phenotype. He is currently working on optimizing ultrasound-mediated gene delivery and therapeutic transducer designs, with the aim of increasing transfection efficiency while also reducing tissue damage.
He holds a BS in bioengineering from the University of Washington.
Research Scientist III
Xuefeng Wang’s main research interest focuses on in vivo gene therapy of hemophilia studies including transient immune suppression to enhance viral transduction; designing factor VIII with high bioactivity, low immunogenicity, and extended half-life; and personalized factor VIII gene editing. Her most recent project tries to translate intraosseous delivery of lentiviral vectors in hemophilia A mice into humanized NSG mice.
Wang holds a PhD degree in biomaterials from Shanghai Jiao Tong University (China). She completed a postdoctoral fellowship in biomineralization at Georgia Institute of Technology and a postdoctoral fellowship for in vivo gene therapy of hemophilia at Seattle Children's Research Institute.